| 51 |
33306753 | The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer. | 2020 Sep-Dec |
2 |
| 52 |
33642751 | Diagnostic Accuracy of Prebiopsy Ga-68 PSMA PET/CT in Detecting Primary Prostate Carcinomas with Prostate-Specific Antigen <50 ng/ml. | 2020 Oct-Dec |
2 |
| 53 |
30132104 | 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. | 2019 Mar |
2 |
| 54 |
30215174 | [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer. | 2019 Jun |
1 |
| 55 |
30671137 | Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review. | 2019 Jan-Dec |
1 |
| 56 |
30890448 | A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. | 2019 Jul 15 |
4 |
| 57 |
31021525 | Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution. | 2019 Aug |
1 |
| 58 |
31119056 | 68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. | 2019 Feb |
1 |
| 59 |
31338731 | 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. | 2019 Oct |
1 |
| 60 |
31361648 | 68Ga-PSMA Uptake in Escherichia coli Spondylodiscitis. | 2019 Nov |
1 |
| 61 |
31516365 | Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer. | 2019 Jul-Sep |
1 |
| 62 |
29393268 | Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging. | 2018 |
1 |
| 63 |
29619657 | Hallmarks in prostate cancer imaging with Ga68-PSMA-11-PET/CT with reference to detection limits and quantitative properties. | 2018 Apr 4 |
1 |
| 64 |
29687208 | Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. | 2018 Sep |
4 |
| 65 |
29939893 | Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. | 2018 Sep |
1 |
| 66 |
30281701 | Clinical perspectives of PSMA PET/MRI for prostate cancer. | 2018 Sep 21 |
1 |
| 67 |
30300002 | Improving Diagnosis of Primary Prostate Cancer With Combined 68Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters. | 2018 Dec |
1 |
| 68 |
28576423 | [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive]. | 2017 Jun - Jul |
1 |
| 69 |
26790588 | The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy. | 2016 Sep |
2 |